Name

Lumitron Technologies

Legal name

Lumitron Holdings Inc

Website

https://lumitronxrays.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Medical Imaging Equipment

NAICS

Irradiation Apparatus Manufacturing (334517), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)

akta.pro primary industry

X-ray & Fluoroscopy Systems (HLAHABAA)

akta.pro secondary industries

Radiation Oncology (HLAKAFAC), Nuclear Medicine & Molecular Imaging (SPECT/PET) (HLAHABAE)

Keywords

• Laser-compton x-ray
• Medical imaging systems
• Radiation therapy devices
• Non-destructive evaluation
• Accelerator-based imaging

Headquarters

HQ city

Irvine

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Infrastructure, Operations, Marketing or Sales

Revenue model

1. X-ray and VHEE System Hardware Sales: Sale of HyperVIEW EBCS X-ray systems to healthcare providers, research institutions, and industrial customers. Systems are comparable in size to MRI or CT instruments and represent the core product line.
2. Licensing and Technology Rights: Lumitron holds exclusive commercial development rights to proprietary X-ray and laser technology developed at Lawrence Livermore National Laboratory. Revenue may be generated through licensing arrangements.
3. US Government Research Contracts: The company has been awarded multiple US Government research contracts supporting R&D activities, representing a revenue stream for technology development.
4. Industrial Application Partnerships: Active programs with major industry leaders in healthcare and non-destructive materials analysis generating revenue through collaboration agreements.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

Lumitron Technologies develops and commercializes advanced laser-Compton X-ray imaging and radiotherapy systems through its HyperVIEW platform. The systems provide up to 1,000x higher resolution and 100x lower radiation dose than conventional X-rays, enabling cellular-level imaging and VHEE FLASH radiotherapy for cancer treatment in a form factor comparable to MRI or CT instruments. Core technology is the proprietary Distributed Charge Compton Source (DCCS) exclusively licensed from Lawrence Livermore National Laboratory.

Product overview

Lumitron Technologies has developed a unified product portfolio anchored by the HyperVIEW platform, which encompasses multiple integrated systems: the HyperVIEW X-Ray System (FDA Breakthrough Device-designated for breast cancer detection), the HyperVIEW EBCS (Extremely Bright Compton Source) for high-resolution imaging, and the HyperVIEW VHEE FLASH Radiotherapy Platform for cancer treatment. All products are powered by the proprietary Distributed Charge Compton Source (DCCS) technology developed at Lawrence Livermore National Laboratory. The platform delivers up to 1000x resolution improvement and 100x dose reduction compared to conventional X-rays, enabling cellular-level imaging and treatment capabilities previously only possible at billion-dollar synchrotron facilities.

Differentiator

Problem solved

Functional benefit

Brands

• HyperVIEW: Lumitron's flagship imaging platform using laser-Compton X-ray technology that delivers up to 1000x resolution improvement and 100x lower radiation dose compared to standard X-rays. The platform enables cellular-level imaging and treatment for medical and industrial applications.
• HyperVIEW EBCS
• HyperVIEW X-Ray System

Products and services

• HyperVIEW X-Ray System An FDA Breakthrough Device-designated X-ray imaging system using proprietary laser-Compton technology and K-Edge subtraction technique for contrast-enhanced cancer detection, providing 100x higher resolution with significantly lower radiation dose than standard X-rays, targeting breast cancer diagnosis in hospital settings.
• HyperVIEW EBCS (Extremely Bright Compton Source) A compact electron beam and X-ray technology platform that collides near-light-speed electron beams with laser beams to produce high-energy X-ray beams, delivering imaging at 1,000x higher resolution and/or 100x lower dose than conventional X-rays for research institutes, university hospitals, and industrial customers.
• HyperVIEW VHEE FLASH Radiotherapy Platform An image-guided radiotherapy platform featuring the world's first compact Very High Energy Electron (VHEE) FLASH-ready source, enabling cancer cell destruction at rates billions of times faster than standard clinical radiation sources while preserving healthy tissue, with potential for image-guided treatment in a single session.

Quantifiable outcome

• 1,000x higher resolution imaging compared to conventional X-rays (effective X-ray spot size of ~100 nanometers vs. 600-800 microns in conventional systems)
• +5 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature8 records

Partnerships

Five partnerships are on record, tiered core.

• Lawrence Livermore National Laboratory (LLNL)coreTechnology or Integration · 7 September 2018Lumitron holds exclusive commercial development rights to proprietary X-ray and laser technology conceived and developed at LLNL. The technology leverages more than $220 million of R&D investment by the US Department of Energy. Chris Barty, Lumitron's CTO, spent 17 years at LLNL and invented the core technologies upon which Lumitron's systems are based. Richard Rankin, Director of LLNL's Innovation and Partnerships Office, noted that the technology transfer represents a major step forward for public benefit.
• University of California, Irvine / Beckman Laser InstitutecoreStrategic or Co-development Partner · 7 September 2018Lumitron established its global R&D and manufacturing facility within UCI's Research Park, co-located with the Beckman Laser Institute and Medical Clinic. The company works collaboratively with UCI's research teams, including Professor Bruce Tromberg (Director of Beckman Laser Institute), to explore implementation possibilities. Professor Barty is a Distinguished Professor at UCI in Physics, Astronomy, Surgery, and the Beckman Laser Institute.
• SLAC National Accelerator LaboratorycoreTechnology or IntegrationSLAC National Accelerator Laboratory jointly developed the high-gradient X-band radio-frequency accelerator technology with LLNL that enables Lumitron's compact, high-flux laser-Compton light source operation.
• World's Largest Commercial Imaging GroupcoreStrategic or Co-development PartnerLumitron has signed an agreement with one of the world's largest commercial imaging groups showing the potential for wide-scale adoption of the HyperVIEW breakthrough technology across the group's global operations.
• Major Industry Leaders (Healthcare and Non-Destructive Materials)coreTechnology or IntegrationLumitron has multiple active programs with major industry leaders in healthcare and non-destructive materials analysis, including programs for developing new medical imaging and therapy applications as well as industrial inspection solutions.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Varian Medical Systems (a Siemens Healthineers company): Varian is the dominant commercial vendor of linear accelerator-based radiation therapy systems and software. While not a laser-Compton source, it directly competes with Lumitron's VHEE FLASH radiotherapy ambitions in the same oncology treatment planning and delivery category that Lumitron targets.
• Elekta: Elekta is a global leader in radiation therapy and radiosurgery hardware (Elekta Unity, Versa HD, Gamma Knife). It competes with Lumitron in the radiotherapy equipment market and shares the same hospital and cancer center customer base that Lumitron targets with HyperVIEW.
• GE HealthCare: GE HealthCare is a global leader in medical imaging (CT, MRI, X-ray, PET/CT). Lumitron's HyperVIEW directly targets the diagnostic X-ray and advanced imaging categories where GE has dominant share, making GE both a competitive threat and a potential strategic partner or acquirer.
• Siemens Healthineers: Siemens Healthineers is a top-tier imaging and radiotherapy vendor (through its Varian acquisition) with strengths in CT, angiography, and now linear accelerators. It competes broadly with HyperVIEW across imaging and therapy categories.
• Philips Healthcare: Philips is a major provider of diagnostic imaging systems (CT, MRI, X-ray) and image-guided intervention solutions. It is a broad incumbent in the hospital imaging equipment category where Lumitron seeks to displace legacy X-ray systems.

Direct peers

• Accuray: Accuray develops CyberKnife and TomoTherapy radiation therapy systems for image-guided, precision radiotherapy. It is a closer comparable to Lumitron in size, growth profile, and innovation narrative within the radiation oncology equipment category, both targeting advanced precision treatments.
• ViewRay: ViewRay pioneered MR-guided radiation therapy (MRIdian) combining imaging and treatment in a single platform. Its image-guided radiotherapy thesis and hardware-heavy, innovation-led positioning closely mirror Lumitron's HyperVIEW dual imaging-treatment value proposition.
• RefleXion Medical: RefleXion develops biology-guided radiotherapy (BgRT) using PET signals to guide treatment. It is a smaller, innovation-driven competitor pursuing next-generation image-guided radiotherapy modalities that overlap with Lumitron's imaging-plus-treatment platform thesis.
• Hologic: Hologic is the leading vendor of mammography and breast health imaging systems, including 3D tomosynthesis. Lumitron's HyperVIEW K-Edge mammography Breakthrough Device directly targets Hologic's core breast imaging franchise, making it the most direct peer in women's health imaging.

Emerging players

• Mevion Medical Systems: Mevion pioneered compact proton therapy systems using accelerator technology. Like Lumitron, it commercializes accelerator-based next-generation radiation therapy in a smaller hospital-deployable form factor, addressing the same unmet need for compact, precision radiotherapy sources.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/lumitron-technologies

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lumitron Technologies